Scandion Oncology

Scandion Oncology A/S is a listed Danish biotechnology company with the mission to address one of the most important challenges in modern oncology – the effective treatment of cancer which has developed resistance towards existing cancer medicine. The company’s first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients.

The company also has several preclinical programs to build a broader pipeline of drugs for the treatment of drug resistant cancer diseases

Contact name:

Bo Rode Hansen

Address:

Fruebjergvej 3, 2100 Copenhagen, Denmark

Telephone:

+45 38 10 20 17

Established:

2017

Number of employees:

10

If you cannot find what you are looking for or if you have feedback to our website, please do not hesitate to contact dd@danskbiotek.dk or +45 5150 0560

Copyright 2021 Danskbiotek. All rights reserved.